GRADE guidelines: 3. Rating the quality of evidence (confidence in the estimates of effect);GRADE-Leitlinien: 3. Bewertung der Qualität der Evidenz (Vertrauen in die Effektschätzer)

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen

Volumn 106, Issue 6, 2012, Pages 449-456

  Meerpohl, Joerg J ^a   Langer, Gero ^b   Perleth, Matthias ^c   Gartlehner, Gerald ^d   Kaminski Hartenthaler, Angela ^d   Schünemann, Holger ^e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^c Abteilung Fachberatung Medizin   (Germany)

^d DANUBE UNIVERSITY KREMS   (Austria)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

body of evidence; GRADE; imprecision; inconsistency; indirectness; publication bias; quality of evidence

Indexed keywords

EID: 84864861699     PISSN: 18659217     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.zefq.2012.06.013     Document Type: Article

References (16)

1. G. Guyatt, A.D. Oxman, E.A. Akl, R. Kunz, G. Vist, and J. Brozek GRADE guidelines: 1, Introduction-GRADE evidence profiles and summary of findings tables J Clin Epidemiol 64 2011 383 394
2. G.H. Guyatt, A.D. Oxman, R. Kunz, D. Atkins, J. Brozek, and S. Norris GRADE guidelines: 2 Framing the question and deciding on important outcomes J Clin Epidemiol 64 2011 395 400
3. G.H. Guyatt, A.D. Oxman, G. Vist, R. Kunz, J. Brozek, and P. Alonso-Coello GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias) J Clin Epidemiol 64 2011 407 415
4. G.H. Guyatt, A.D. Oxman, V. Montori, G.E. Vist, R. Kunz, and J. Brozek GRADE guidelines: 5. Rating the quality of evidence - publication bias J Clin Epidemiol 64 2011 1277 1282
5. G.H. Guyatt, A.D. Oxman, R. Kunz, J. Brozek, P. Alonso-Coello, and D. Rind GRADE guidelines: 6. Rating the quality of evidence - imprecision J Clin Epidemiol 64 2011 1283 1293
6. G.H. Guyatt, A.D. Oxman, R. Kunz, J.W. von, J. Brozek, and M. Helfand GRADE guidelines: 7. Rating the quality of evidence - inconsistency J Clin Epidemiol 64 2011 1294 1302
7. G.H. Guyatt, A.D. Oxman, R. Kunz, J.W. von, J. Brozek, and M. Helfand GRADE guidelines: 8. Rating the quality of evidence - indirectness J Clin Epidemiol 64 2011 1303 1310
8. R.J. Waldman, W.N. Hall, H. McGee, and G. Van Amburg Aspirin as a risk factor in Reye's syndrome JAMA 247 1982 3089 3094
9. K.M. Starko, C.G. Ray, L.B. Dominguez, W.L. Stromberg, and D.F. Woodall Reye's syndrome and salicylate use Pediatrics 66 1980 859 864
10. T.J. Halpin, F.J. Holtzhauer, R.J. Campbell, L.J. Hall, A. Correa-Villasenor, and R. Lanese Reye's syndrome and medication use JAMA 248 1982 687 691
11. E.S. Hurwitz, M.J. Barrett, D. Bregman, W.J. Gunn, P. Pinsky, and L.B. Schonberger Public Health Service study of Reye's syndrome and medications. Report of the main study JAMA 257 1987 1905 1911
12. C. Kearon, M. Gent, J. Hirsh, J. Weitz, M.J. Kovacs, and D.R. Anderson A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism NEJM 340 1999 901 907
13. I.A. Campbell, D.P. Bentley, R.J. Prescott, P.A. Routledge, H.G. Shetty, and I.J. Williamson Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial BMJ 334 2007 674
14. C. Kearon, J.S. Ginsberg, D.R. Anderson, M.J. Kovacs, P. Wells, and J.A. Julian Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor J Thromb Haemost 2 2004 743 749
15. G. Agnelli, P. Prandoni, M.G. Santamaria, P. Bagatella, A. Iorio, and M. Bazzan Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators NEJM 345 2001 165 169
16. G.H. Guyatt, A.D. Oxman, G.E. Vist, R. Kunz, Y. Falck-Ytter, and P. Alonso-Coello GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926